If you've been researching GLP-1 medications, you've probably noticed that Ozempic and Wegovy seem remarkably similar. That's because they are — both contain the exact same active ingredient: semaglutide, manufactured by Novo Nordisk. So why do two separate products exist, and does it matter which one you're prescribed?

The Molecule: Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a natural hormone your body produces after eating, which helps regulate blood sugar levels and appetite. The molecule is identical in both Ozempic and Wegovy — same chemical structure, same mechanism of action, same manufacturer.

Both have a half-life of approximately 7 days, which is why both are administered as once-weekly subcutaneous injections.

The Key Difference: What They're Approved For

The fundamental distinction is regulatory approval — each product went through separate clinical trial programs for different conditions:

  • Ozempic is FDA-approved for type 2 diabetes management. It was approved in 2017 to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise.
  • Wegovy is FDA-approved for chronic weight management. It was approved in 2021 for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition.

Dose Ranges: Wegovy Goes Higher

This is a clinically significant difference. While both medications use a gradual dose escalation schedule, their maximum doses differ:

Ozempic titration: 0.25 mg (weeks 1-4) → 0.5 mg (maintenance or step) → 1.0 mg → 2.0 mg (maximum). Wegovy titration: 0.25 mg (weeks 1-4) → 0.5 mg (weeks 5-8) → 1.0 mg (weeks 9-12) → 1.7 mg (weeks 13-16) → 2.4 mg (maintenance maximum).

The higher maximum dose of Wegovy (2.4 mg vs 2.0 mg) reflects the clinical trial data showing that higher doses produced greater weight loss. The STEP clinical trial program demonstrated that semaglutide 2.4 mg produced an average of approximately 15% body weight loss over 68 weeks.

Pharmacokinetics: Identical Behavior

Since the molecule is identical, the pharmacokinetic profile is the same regardless of brand:

  • Half-life: approximately 7 days (168 hours)
  • Time to peak: 1-3 days after injection
  • Steady state: reached after approximately 4-5 weeks of weekly dosing
  • Full clearance: approximately 35 days (5 half-lives) after the last dose

Insurance and Cost Considerations

This is where the distinction between the two products has the most day-to-day impact for many patients. Because they have different approved indications, insurance coverage varies significantly:

  • Ozempic is more commonly covered by insurance plans because diabetes treatment is broadly covered. Many patients with type 2 diabetes can access it with reasonable copays.
  • Wegovy coverage is less universal. Many insurance plans exclude weight management medications, though coverage has been expanding as evidence of cardiovascular benefits grows.

Without insurance, both medications have a list price of roughly $1,000-1,300 per month in the United States. Manufacturer savings programs and pharmacy coupons can reduce out-of-pocket costs in some cases.

Can You Switch Between Them?

Because they contain the same molecule, switching between Ozempic and Wegovy is pharmacologically straightforward. However, this should always be done under your doctor's supervision. Your doctor will consider your current dose, the reason for switching, and insurance implications. Never switch medications on your own.

The bottom line: Ozempic and Wegovy are the same drug (semaglutide) packaged and approved for different conditions. The choice between them depends on your diagnosis, your doctor's recommendation, and your insurance coverage — not on any molecular difference.